DRKS00014659Active, not recruitingNot Applicable
Evaluation of the predictive power of the CD147/EMMPRIN concentration in peripheral blood of patients with multiple myeloma - IMiD-Praedict
Arbeitsgruppe Prof. Bassermann, Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der Technischen Universität München0 sites25 target enrollmentStarted: April 24, 2018Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 25
Study Overview
Brief Summary
After enrolment of 25 patients with multiple myeloma, an interim analysis was performed. Unfortunately, the results didn’t show any evidence that the hypothesis of the scientific examination is true. The CD147 serum levels didn’t correlate with the response to therapy of the patients. Neither the initial absolute CD147 concentration nor the CD147 serum levels over time showed any significant correlation concerning response to therapy or disease progression. Serum levels of CD147 don’t seem to be a reliable biomarker for the prediction of therapy response in patients with multiple myeloma.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- All
Inclusion Criteria
- •Start/change of treatment of a patient with newly diagnosed/relapsed Multiple Myeloma with measurable paraprotein;
- •performance status ECOG Patients have to be treated routinely in the departement of internal medicine III of the university clinics of the technical university Munich.
Exclusion Criteria
- •non-secretory multiple myeloma;
- •HIV/ active Hep B/C infection;
- •other malignant disease
Investigators
Similar Trials
Recruiting
Not Applicable
Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple MyelomaMultiple MyelomaNCT05693012Qiu Lugui398
Recruiting
Not Applicable
Biomarkers in Multiple MyelomaHematological PatientsNewly Diagnosed Multiple MyelomaChemotherapyNCT05259553Centre Hospitalier Universitaire de Saint Etienne70
Completed
Phase 2
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple MyelomaSmoldering MyelomaSmoldering Multiple MyelomaNCT02279394Dana-Farber Cancer Institute51
Recruiting
Not Applicable
Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple MyelomaMultiple MyelomaNCT06302699Institute of Hematology & Blood Diseases Hospital, China80
Completed
Phase 1
Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple MyelomaRelapsed and/or Refractory Multiple MyelomaNCT00882063Piramal Enterprises Limited19